Ardelyx rises as it begins late-stage test of constipation drug

Shares of drugmaker Ardelyx ARDX.O rise 1.01% to $7.97 premarket

 Co says it has begun dosing patients in a late-stage trial testing Ibsrela in adults with chronic idiopathic constipation, a long-term condition that causes infrequent or difficult bowel movements

The  trial will enroll about 700 adults and compare Ibsrela with placebo over 26 weeks; initial results expected in H2 2027, per co

ARDX's Ibsrela is already approved in the U.S. for irritable bowel syndrome with constipation; co aims to expand use to chronic idiopathic constipation

 Most common side effects include diarrhea, gas, abdominal swelling and dizziness, co says

Shares up ~15% in 2025